Market Research Logo

Pulmonary Embolism - Pipeline Review, H2 2015

Pulmonary Embolism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H2 2015’, provides an overview of the Pulmonary Embolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Embolism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism Overview
Therapeutics Development
Pipeline Products for Pulmonary Embolism - Overview
Pipeline Products for Pulmonary Embolism - Comparative Analysis
Pulmonary Embolism - Therapeutics under Development by Companies
Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes
Pulmonary Embolism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pulmonary Embolism - Products under Development by Companies
Pulmonary Embolism - Products under Investigation by Universities/Institutes
Pulmonary Embolism - Companies Involved in Therapeutics Development
Bayer AG
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Pulmonary Embolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
apixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SMTP-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmonary Embolism - Recent Pipeline Updates
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE
Dec 03, 2013: New Data to be Presented on Bayer’s Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pulmonary Embolism, H2 2015
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Pulmonary Embolism - Pipeline by Bayer AG, H2 2015
Pulmonary Embolism - Pipeline by Bristol-Myers Squibb Company, H2 2015
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H2 2015
Pulmonary Embolism - Dormant Projects, H2 2015
Pulmonary Embolism - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pulmonary Embolism, H2 2015
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report